Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies

Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative commensal bacterium and opportunistic pathogen. In healthy individuals, the innate immune system is adept at protecting against K. pneumoniae infection. Notably, the serum complement system and phagocytic leukocytes (e.g., neutrophils) are hig...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Clement Opoku-Temeng, Natalia Malachowa, Scott D. Kobayashi, Frank R. DeLeo
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	antibiotic resistance phagocytosis neutrophil capsule polysaccharide vaccine Medicine R Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/19dc743ae6d5490abe522b9b9065d2a0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19dc743ae6d5490abe522b9b9065d2a0
record_format	dspace
spelling	oai:doaj.org-article:19dc743ae6d5490abe522b9b9065d2a02021-11-04T14:40:31ZInnate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies1662-811X1662-812810.1159/000518679https://doaj.org/article/19dc743ae6d5490abe522b9b9065d2a02021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/518679https://doaj.org/toc/1662-811Xhttps://doaj.org/toc/1662-8128Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative commensal bacterium and opportunistic pathogen. In healthy individuals, the innate immune system is adept at protecting against K. pneumoniae infection. Notably, the serum complement system and phagocytic leukocytes (e.g., neutrophils) are highly effective at eliminating K. pneumoniae and thereby preventing severe disease. On the other hand, the microbe is a major cause of healthcare-associated infections, especially in individuals with underlying susceptibility factors, such as pre-existing severe illness or immune suppression. The burden of K. pneumoniae infections in hospitals is compounded by antibiotic resistance. Treatment of these infections is often difficult largely because the microbes are usually resistant to multiple antibiotics (multidrug resistant [MDR]). There are a limited number of treatment options for these infections and new therapies, and preventative measures are needed. Here, we review host defense against K. pneumoniae and discuss recent therapeutic measures and vaccine approaches directed to treat and prevent severe disease caused by MDR K. pneumoniae.Clement Opoku-TemengNatalia MalachowaScott D. KobayashiFrank R. DeLeoKarger Publishersarticleantibiotic resistancephagocytosisneutrophilcapsule polysaccharidevaccineMedicineRInternal medicineRC31-1245ENJournal of Innate Immunity, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antibiotic resistance phagocytosis neutrophil capsule polysaccharide vaccine Medicine R Internal medicine RC31-1245
spellingShingle	antibiotic resistance phagocytosis neutrophil capsule polysaccharide vaccine Medicine R Internal medicine RC31-1245 Clement Opoku-Temeng Natalia Malachowa Scott D. Kobayashi Frank R. DeLeo Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies
description	Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative commensal bacterium and opportunistic pathogen. In healthy individuals, the innate immune system is adept at protecting against K. pneumoniae infection. Notably, the serum complement system and phagocytic leukocytes (e.g., neutrophils) are highly effective at eliminating K. pneumoniae and thereby preventing severe disease. On the other hand, the microbe is a major cause of healthcare-associated infections, especially in individuals with underlying susceptibility factors, such as pre-existing severe illness or immune suppression. The burden of K. pneumoniae infections in hospitals is compounded by antibiotic resistance. Treatment of these infections is often difficult largely because the microbes are usually resistant to multiple antibiotics (multidrug resistant [MDR]). There are a limited number of treatment options for these infections and new therapies, and preventative measures are needed. Here, we review host defense against K. pneumoniae and discuss recent therapeutic measures and vaccine approaches directed to treat and prevent severe disease caused by MDR K. pneumoniae.
format	article
author	Clement Opoku-Temeng Natalia Malachowa Scott D. Kobayashi Frank R. DeLeo
author_facet	Clement Opoku-Temeng Natalia Malachowa Scott D. Kobayashi Frank R. DeLeo
author_sort	Clement Opoku-Temeng
title	Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies
title_short	Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies
title_full	Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies
title_fullStr	Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies
title_full_unstemmed	Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies
title_sort	innate host defense against klebsiella pneumoniae and the outlook for development of immunotherapies
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/19dc743ae6d5490abe522b9b9065d2a0
work_keys_str_mv	AT clementopokutemeng innatehostdefenseagainstklebsiellapneumoniaeandtheoutlookfordevelopmentofimmunotherapies AT nataliamalachowa innatehostdefenseagainstklebsiellapneumoniaeandtheoutlookfordevelopmentofimmunotherapies AT scottdkobayashi innatehostdefenseagainstklebsiellapneumoniaeandtheoutlookfordevelopmentofimmunotherapies AT frankrdeleo innatehostdefenseagainstklebsiellapneumoniaeandtheoutlookfordevelopmentofimmunotherapies
_version_	1718444822183804928

Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies

Ejemplares similares